Literature DB >> 2564958

Haemopoietic growth factors 2: clinical applications.

D Metcalf1.   

Abstract

Mesh:

Substances:

Year:  1989        PMID: 2564958     DOI: 10.1016/s0140-6736(89)92874-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  A case of POEMS syndrome associated with essential thrombocythaemia and dermal mastocytosis.

Authors:  A Jackson; I E Burton
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

Review 2.  New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.

Authors:  N Thatcher
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

Review 3.  Immunomodulators. Future prospects.

Authors:  B C Takx-Köhlen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 4.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

5.  Carbimazole induced agranulocytosis: rescue with human recombinant granulocyte colony stimulating factor.

Authors:  J A O'Hare; T Azher
Journal:  Ir J Med Sci       Date:  1997 Oct-Dec       Impact factor: 1.568

Review 6.  Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results.

Authors:  E Liehl; J Hildebrandt; C Lam; P Mayer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

7.  Improvement of neutropenia and neutrophil dysfunction by granulocyte colony-stimulating factor in a patient with glycogen storage disease type Ib.

Authors:  A Ishiguro; T Nakahata; T Shimbo; Y Amano; K Yasui; K Koike; A Komiyama
Journal:  Eur J Pediatr       Date:  1993-01       Impact factor: 3.183

Review 8.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.